Abstract
Once patient of acute lymphoblastic leukemia (ALL) is in clinical remission, more sensitive tools than morphology are required to assess minimal residual disease (MRD), to guide clinicians in management of the disease. In the present time, MRD assessment by flow cytometry and molecular methods has emerged as the single most useful prognostic factor in ALL. The chapter deals with definition, technique, utility, and prognostic implications of MRD measurement in ALL.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Thomas A. How can we improve on the already impressive results in pediatric ALL? Hematology Am Soc Hematol Educ Program. 2015;2015(1):414–9.
Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999;38(4):139–52.
Bradstock KF, Janossy G, Tidman N, Papageorgiou ES, Prentice HG, Willoughby M, et al. Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. Leuk Res. 1981;5(4–5):301–9.
Gaipa G, Basso G, Biondi A, Campana D. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia: MRD in pediatric ALL. Cytometry B Clin Cytom. 2013;84(6):359–69.
van Dongen JJM, van der Velden VHJ, Bruggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996–4009.
Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008;111(12):5477–85.
Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, et al. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Br J Haematol. 2009;146(3):292–9.
Borowitz MJ, Wood BL, Devidas M, Loh ML, Raetz EA, Salzer WL, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood. 2015;126(8):964–71.
Ikoma MRV, Beltrame MP, Ferreira SIACP, Souto EX, Malvezzi M, Yamamoto M. Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia. Rev Bras Hematol Hemoter. 2015;37(6):406–13.
Bradstock K, Papageorgiou ES, Janossy G, Hoffbrand AV, Willoughby M, Roberts P, et al. Detection of leukæmic lymphoblasts in CSF by immunofluorescence for terminal transferase. Lancet. 1980;315(8178):1144.
Pedreira CE, Costa ES, Lecrevisse Q, van Dongen JJM, Orfao A, EuroFlow Consortium. Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends Biotechnol. 2013;31(7):415–25.
Brady KA, Atwater SK, Lowell CA. Flow cytometric detection of CD10 (cALLA) on peripheral blood B lymphocytes of neonates. Br J Haematol. 1999;107(4):712–5.
McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood. 2001;98(8):2498–507.
Chantepie SP, Cornet E, Salaün V, Reman O. Hematogones: an overview. Leuk Res. 2013;37(11):1404–11.
McPherson R, Pincus M. Henry’s clinical diagnosis and management by laboratory methods E-book. Philadelphia: Elsevier Health Sciences; 2016.
Dworzak MN, Gaipa G, Ratei R, Veltroni M, Schumich A, Maglia O, et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: multicentric assessment is feasible. Cytometry B Clin Cytom. 2008;74B(6):331–40.
Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2011;117(23):6267–76.
Czader M. Hematological malignancies. Totowa: Humana Press; 2013.
Shaver AC, Greig BW, Mosse CA, Seegmiller AC. B-ALL minimal residual disease flow cytometry: an application of a novel method for optimization of a single-tube model. Am J Clin Pathol. 2015;143(5):716–24.
6 flow cytometry gating tips that most scientists forget|expert cytometry|flow cytometry training [internet]. Expert cytometry. 2014 [cited 2017 Dec 18]. https://expertcytometry.com/6-flow-cytometry-gating-tips-that-most-scientists-forget/.
Ghodke K, Bibi A, Rabade N, Patkar N, Subramanian PG, Kadam PA, et al. CD19 negative precursor B acute lymphoblastic leukemia (B-ALL)-immunophenotypic challenges in diagnosis and monitoring: a study of three cases: CD19 negative precursor B-ALL-immunophenotypic challenges in diagnosis and monitoring. Cytometry B Clin Cytom. 2017;92(4):315–8.
Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2017;129(3):347–57.
Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia. 2010;24(3):521–35.
Gleissner B, Rieder H, Thiel E, Fonatsch C, Janssen LA, Heinze B, et al. Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data. Leukemia. 2001;15(12):1834–40.
Mitterbauer G, Nemeth P, Wacha S, Cross NC, Schwarzinger I, Jaeger U, et al. Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. Br J Haematol. 1999 Sep;106(3):634–43.
Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22(4):771–82.
Vora AJ, Goulden N, Mitchell CD, Hough R, Rowntree C, Richards SM. UKALL 2003, a randomised trial investigating treatment intensification for children and young adults with minimal residual disease defined high risk acute lymphoblastic leukaemia. Blood. 2012;120(21):136.
Rambaldi A, Borleri G, Dotti G, Bellavita P, Amaru R, Biondi A, et al. Innovative two-step negative selection of granulocyte colony-stimulating factor–mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation. Blood. 1998;91(6):2189–96.
Patkar N, Alex A, Bargavi B, Ahmed R, Abraham A, George B, Vishwabandya A, Srivastava A, Mathews V. Standardization minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country. Cytometry B Clin Cytom. 2012;82B:252–8.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Chauhan, R., Juneja, R., Sharma, R., Saxena, R. (2019). Minimal Residual Disease in Acute Lymphoblastic Leukemia. In: Saxena, R., Pati, H. (eds) Hematopathology. Springer, Singapore. https://doi.org/10.1007/978-981-13-7713-6_12
Download citation
DOI: https://doi.org/10.1007/978-981-13-7713-6_12
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-7712-9
Online ISBN: 978-981-13-7713-6
eBook Packages: MedicineMedicine (R0)